Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 19Colorectal Neoplasms 11Colonic Neoplasms 7Brain Neoplasms 6Rectal Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Thyroid Neoplasms 1Solid Tumor 1Skin Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Multiple Myeloma 1Gliosarcoma 1Glioma 1Glioblastoma 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Astrocytoma 1Advanced BRAF Mutant Cancers 1

Interventions

Gemcitabine 406Oxaliplatin 131Fluorouracil 125130-nm albumin-bound paclitaxel 108Capecitabine 100Albumin-Bound Paclitaxel 90Leucovorin 88Irinotecan 87Radiotherapy 76Radiosurgery 64Taxes 63Cisplatin 56Erlotinib Hydrochloride 44Drug Therapy 42folfirinox 40Magnetic Resonance Spectroscopy 39pembrolizumab 35Blood Specimen Collection 33S 1 (combination) 31Pancreaticoduodenectomy 31Docetaxel 31Nivolumab 30Bevacizumab 30Biopsy 26Surgical Procedures, Operative 25Cyclophosphamide 25irinotecan sucrosofate 24Specimen Handling 24Radiation 22Standard of Care 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pancreatic Neoplasms × encorafenib × Clear all
NCT04390243 2024-05-06

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

Academic and Community Cancer Research United

Phase 2 Terminated
6 enrolled 16 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡